34
https://pubmed.ncbi.nlm.nih.gov/38115313
The abstract reports a cost-effectiveness analysis that suggests sotorasib could potentially be a cost-effective therapy for advanced non-small-cell lung cancer patients with KRAS p.G12C-mutation in the US and China, but only following price reductions.